🔗 Share this article The Global Health Body Raises Alert Over Severe Scarcity of Weight-Loss Medications Less than a tenth of patients who could benefit from weight-loss injections including Wegovy have access to them, caution the World Health Organization as it releases its first recommendations on the medications. With in excess of 1,000,000,000 individuals worldwide now living with obesity, it is advocating for increased and just availability to this class of drugs. Based on forecasts, over two billion could be living with obesity by 2030 without intervention. "Our latest guidance affirms that excess weight is a long-term condition that can be addressed with comprehensive and lifelong support," said its chief Tedros Adhanom Ghebreyesus. Significant expense, insufficient output, and supply-chain constraints are key obstacles to widespread access to the injections that can assist patients in reducing substantial body mass, notes the body. Skinny Jab Shortage Despite the current most optimistic outlook, the manufacturing of such drugs might only reach approximately 100 million people – fewer than 10% of the global need, according to the health organization. The advice calls on nations and manufacturers to widen availability, via measures like voluntary licensing. A patent on the active ingredient – the core component of a leading brand – is scheduled to end in multiple countries in 2026. The Way Obesity Drugs Work These medications mimick a natural hormone to delay gastric emptying, curb appetite and increase feelings of fullness so users consume fewer calories. Patients typically see weight reduction in the initial weeks of commencing the weekly injections. Studies indicates users may see weight return after a year of discontinuing the treatment, as their typical hunger come back. Being above a healthy weight raises your risk for developing health problems, such as type 2 diabetes, cardiovascular issues, brain attack, and certain cancers. Excess weight concerns people in every country and was linked to 3.7 million fatalities worldwide in 2024, per the health agency.
Less than a tenth of patients who could benefit from weight-loss injections including Wegovy have access to them, caution the World Health Organization as it releases its first recommendations on the medications. With in excess of 1,000,000,000 individuals worldwide now living with obesity, it is advocating for increased and just availability to this class of drugs. Based on forecasts, over two billion could be living with obesity by 2030 without intervention. "Our latest guidance affirms that excess weight is a long-term condition that can be addressed with comprehensive and lifelong support," said its chief Tedros Adhanom Ghebreyesus. Significant expense, insufficient output, and supply-chain constraints are key obstacles to widespread access to the injections that can assist patients in reducing substantial body mass, notes the body. Skinny Jab Shortage Despite the current most optimistic outlook, the manufacturing of such drugs might only reach approximately 100 million people – fewer than 10% of the global need, according to the health organization. The advice calls on nations and manufacturers to widen availability, via measures like voluntary licensing. A patent on the active ingredient – the core component of a leading brand – is scheduled to end in multiple countries in 2026. The Way Obesity Drugs Work These medications mimick a natural hormone to delay gastric emptying, curb appetite and increase feelings of fullness so users consume fewer calories. Patients typically see weight reduction in the initial weeks of commencing the weekly injections. Studies indicates users may see weight return after a year of discontinuing the treatment, as their typical hunger come back. Being above a healthy weight raises your risk for developing health problems, such as type 2 diabetes, cardiovascular issues, brain attack, and certain cancers. Excess weight concerns people in every country and was linked to 3.7 million fatalities worldwide in 2024, per the health agency.